近期,博瑞医药股价强势七连阳,引发市场热议。表面看,资金热捧源于其在GLP-1类减肥药领域的布局,但细究行业竞争格局及产品同质化问题,这场狂欢背后也存在隐忧。7月10日,CDE官网公布,博瑞医药的双靶点GLP-1/GIP受体激动剂BGM0504片IND申请已获受理。消息公布后,博瑞医药股价连续七个交易日上涨。7月21日,公司股价报收87.31元,涨幅1.18%。博瑞医药的上涨动力主要来自市场对...
Source Link近期,博瑞医药股价强势七连阳,引发市场热议。表面看,资金热捧源于其在GLP-1类减肥药领域的布局,但细究行业竞争格局及产品同质化问题,这场狂欢背后也存在隐忧。7月10日,CDE官网公布,博瑞医药的双靶点GLP-1/GIP受体激动剂BGM0504片IND申请已获受理。消息公布后,博瑞医药股价连续七个交易日上涨。7月21日,公司股价报收87.31元,涨幅1.18%。博瑞医药的上涨动力主要来自市场对...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.